Skip to Main Content

Paper Details

Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.
J Pathol
13
2022
ARID1A, ARID1A mutations, BAF250a, CCOC, CCOCs, CD8, CD8 TIL, CD8 TILs, CD8 tumour-infiltrating lymphocytes, DNA mismatch repair deficiency, ENOC, ENOCs, MMR deficiency, MMRd, Ovarian Tumor, SNF, SWI, clear cell (CCOC) ovarian carcinomas, endometrioid, endometrioid (ENOC), endometriosis-, endometriosis-associated ovarian carcinomas, malignancies, ovarian cancers, ovarian carcinomas, patients, single nucleotide variants, tumour
Author NameAffiliation
Tayyebeh M NazeranUniversity of British Columbia, Vancouver General Hospital
Derek S ChiuUniversity of British Columbia, Vancouver General Hospital
Samuel LeungUniversity of British Columbia, Vancouver General Hospital
Catherine J KennedyThe University of Sydney, The Westmead Institute for Medical Research
Catherine J KennedyWestmead Hospital
Andreas du Bois
Hans-Peter SinnUniversity Hospital Heidelberg, Institute of Pathology
Naveena SinghBarts Health National Health Service Trust
Raghwa SharmaWestmead Hospital
Raghwa SharmaUniversity of Sydney
Raghwa SharmaWestern Sydney University
Alison BrandWestmead Hospital
Alison BrandUniversity of Sydney
Paul HarnettWestmead Hospital
Paul HarnettWestmead Hospital, Crown Princess Mary Cancer Centre
Anna DeFazioThe University of Sydney, The Westmead Institute for Medical Research
Anna DeFazioThe University of Sydney
Anna DeFazioUniversity of Sydney
Anna DeFazioWestmead Hospital
Anna DeFazioThe University of Sydney, The Westmead Institute for Medical Research
Anna DeFazioWestmead Hospital
Anna DeFazioUniversity of Sydney
Anna DeFazioThe University of Sydney
Ren??e T FortnerGerman Cancer Research Center (DKFZ)
Jan LubinskiInternational Hereditary Cancer Centre, Pomeranian Medical University
Jan LubinskiInternational Hereditary Cancer Centre, Pomeranian Medical University
Aleksandra To??oczko-GrabarekInternational Hereditary Cancer Centre, Pomeranian Medical University
Cezary CybulskiInternational Hereditary Cancer Centre, Pomeranian Medical University
Jacek GronwaldInternational Hereditary Cancer Centre, Pomeranian Medical University
Jacek GronwaldInternational Hereditary Cancer Centre, Pomeranian Medical University
Kylie L GorringeThe University of Melbourne
Kylie L GorringePeter MacCallum Cancer Centre
Ian G CampbellThe University of Melbourne
Ian G CampbellPeter MacCallum Cancer Centre
Simon A GaytherCedars-Sinai Medical Center, Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core
Michael E CarneyJohn A. Burns School of Medicine, University of Hawaii
Lynne R WilkensUniversity of Hawaii Cancer Center
Lynne R WilkensUniversity of Hawaii Cancer Center
Marc T GoodmanCedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Linda E KelemenHollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina
Aleksandra Gentry-MaharajUniversity College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology
Aleksandra Gentry-MaharajUniversity College London, Institute for Women's Health
Aleksandra Gentry-MaharajUniversity College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology
Aleksandra Gentry-MaharajUniversity College London, Institute for Women's Health
Martin WidschwendterUniversity of Innsbruck, EUTOPS Institute
Usha MenonUniversity College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology
Usha MenonUniversity College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology
Kelly L BoltonWashington University School of Medicine
Kelly L BoltonWashington University School of Medicine
Jennifer AlsopUniversity of Cambridge
  • 1 - 50

Datasets